Tower Research Capital LLC (Trc) Humanigen, Inc Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.13 - $0.2 $862 - $1,327	-6,637 Reduced 12.54%	46,289 $6,000
Q1 2023 May 09, 2023	BUY	$0.12 - $0.23 $4,037 - $7,739	33,649 Added 174.56%	52,926 $8,000
Q4 2022 Feb 10, 2023	SELL	$0.09 - $0.2 $221 - $491	-2,459 Reduced 11.31%	19,277 $2,000
Q3 2022 Nov 10, 2022	BUY	$0.15 - $3.02 $1,855 - $37,351	12,368 Added 132.02%	21,736 $4,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.33 $10,067 - $19,047	5,720 Added 156.8%	9,368 $16,000
Q1 2022 May 12, 2022	SELL	$1.81 - $3.97 $15,500 - $33,999	-8,564 Reduced 70.13%	3,648 $11,000
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $59,292 - $133,164	-16,200 Reduced 57.02%	12,212 $46,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $152,994 - $460,013	25,800 Added 987.75%	28,412 $168,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $32,171 - $54,030	2,376 Added 1006.78%	2,612 $45,000
Q1 2021 May 17, 2021	SELL	$12.91 - $23.83 $22,747 - $41,988	-1,762 Reduced 88.19%	236 $5,000
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $15,924 - $43,276	1,998 New	1,998 $35,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.